Navigation Links
Treatment over a longer period for blood clotting

Venous thromboembolism is a condition which causes clotting in the veins. Typical therapy for venous thromboembolism includes a five- to 10-day course of heparin followed by three to 12 months of the oral drug warfarin. However, the problem with this treatment is that once the patient goes off warfarin, venous thromboembolism recurs. While recurrence rates of this problem are reduced if the patient stays on warfarin, according to previous studies, it// also puts the patient at an increased risk for a major hemorrhage. Researchers have now conducted a study to find out whether keeping patients on a low-dose of warfarin would be beneficial or too much of a risk.

The study included more than 500 patients who received standard treatment and then were assigned to receive a placebo or low-intensity warfarin. Participants were followed to see who had recurrent venous thromboembolism, major hemorrhage, and who died. After four years, researchers found that 37 of the 253 patients assigned to the placebo had recurrent venous thromboembolism, as compared with 14 of the 255 patients on the low-intensity warfarin. This indicated a risk reduction of 64 percent. Furthermore, major hemorrhage occurred in two patients on the placebo and five on the warfarin. Researchers claimed that the reduction in the risk of recurrent venous thromboembolism for patients on low-intensity warfarin, after adjusting for other factors, was between 76 percent and 81 percent.

Andrew Schafer, M.D., from the University of Pennsylvania School of Medicine, in an accompanying editorial said that though researchers claim short-term treatment reduces the risk of recurrent venous thromboembolism by up to 81 percent, doctors are continuing to walk a tightrope for dosing medicine for patients with venous thromboembolism. Although low-intensity warfarin may prevent recurrent venous thromboembolism it is unclear what dosage doctors need to give to prevent recurrence and not cause major bleedin g.


Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:

(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: